Review: Novel targets in the management of pneumonia-Reference-Cited by-同舟云学术

Review: Novel targets in the management of pneumonia

Published:2008-12 Issue:6 Volume:2 Page:387-400
ISSN:1753-4666
Container-title:Therapeutic Advances in Respiratory Disease
language:en
Short-container-title:Ther Adv Respir Dis

Author:

Díaz Luis A.¹,Mortensen Eric M.²,Anzueto Antonio³,Restrepo Marcos I.⁴

Affiliation:

1. Geisinger Health System and Fundación Universitaria de Ciencias de la Salud, Hospital de San José, Bogotá DC, Colombia

2. General Internal Medicine, VERDICT, South Texas Veterans Health Care System and Audie L Murphy Division, University of Texas Health Science Center, San Antonio, USA

3. Division of Pulmonary and Critical Care Medicine, South Texas Veterans Health Care System and Audie L Murphy Division, University of Texas Health Science Center, San Antonio, USA

4. Division of Pulmonary and Critical Care Medicine, VERDICT, South Texas Veterans Health Care System and Audie L Murphy Division, University of Texas Health Science Center, San Antonio, USA,

Abstract

Community-acquired pneumonia (CAP) is the leading cause of death from infectious diseases in the US. It accounts each year for 500,000 hospitalizations and 45,000 deaths and represents one of the most common causes of intensive care unit (ICU) admission. The mortality rate due to severe CAP has shown little improvement in the past three decades, remaining between 21% and 58% in patients admitted to the intensive care unit. Antimicrobial agents are the cornerstone of therapy against CAP, but there are some novel antibiotic and nonantibiotic therapies that have been recently tested that may potentially impact outcomes of patients with severe CAP. We will review the most recent data regarding novel therapies in patients with the highest risk of death such as those with severe CAP.

Publisher

SAGE Publications

Subject

Pharmacology (medical),Pulmonary and Respiratory Medicine

Link

http://journals.sagepub.com/doi/pdf/10.1177/1753465808098694

Reference120 articles.

1. National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1990-May 1999, Issued June 1999

2. Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia

3. Drotrecogin Alfa (Activated) for Adults with Severe Sepsis and a Low Risk of Death

4. Effect of a Protective-Ventilation Strategy on Mortality in the Acute Respiratory Distress Syndrome

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ceftaroline for severe community-acquired pneumonia: A real-world two-centre experience in Italy and Spain;International Journal of Antimicrobial Agents;2020-04

2. Efficacy of zinc sulphate on in-hospital outcome of community-acquired pneumonia in people aged 50 years and over;The International Journal of Tuberculosis and Lung Disease;2016-05-01

3. Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia in the intensive care unit;Therapeutics and Clinical Risk Management;2015-04

4. D-dimer levels in assessing severity and clinical outcome in patients with community-acquired pneumonia. A secondary analysis of a randomised clinical trial;European Journal of Internal Medicine;2012-07

5. Corticoides en la neumonía: argumentos a favor;Archivos de Bronconeumología;2011-05